ChromaDex Co. (NASDAQ:CDXC) Stake Raised by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of ChromaDex Co. (NASDAQ:CDXC) by 10.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,172 shares of the company’s stock after buying an additional 17,115 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.23% of ChromaDex worth $639,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. OneDigital Investment Advisors LLC boosted its position in ChromaDex by 5.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after acquiring an additional 3,097 shares during the period. Miracle Mile Advisors LLC acquired a new stake in ChromaDex in the second quarter worth about $27,000. The Manufacturers Life Insurance Company bought a new position in ChromaDex in the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex during the 2nd quarter valued at about $32,000. Finally, Lazard Asset Management LLC bought a new stake in shares of ChromaDex during the 1st quarter worth about $43,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Price Performance

CDXC stock opened at $7.64 on Friday. The firm has a market cap of $583.54 million, a PE ratio of 764.76 and a beta of 1.88. ChromaDex Co. has a 12 month low of $1.32 and a 12 month high of $7.89. The firm has a 50 day simple moving average of $4.93 and a 200 day simple moving average of $3.70.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. As a group, sell-side analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current year.

Analyst Ratings Changes

CDXC has been the topic of a number of research analyst reports. Roth Mkm raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright lifted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, StockNews.com lowered ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Monday, November 18th.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.